Cargando…

Development and identification of a prognostic nomogram model for patients with mixed cell adenocarcinoma of the ovary

BACKGROUND: Mixed cell ovarian adenocarcinoma (MCOA) is a malignant gynecologic tumor consisting of serous, mucous, and papillary tumor cells. However, the clinical features and prognosis of MCOA patients are unclear. METHODS: In this study, univariate and multivariate Cox proportional risk models w...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Huijie, Jiang, Shaotao, Zhong, Peiwen, Li, Weiru, Zhang, Siyou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8532325/
https://www.ncbi.nlm.nih.gov/pubmed/34674727
http://dx.doi.org/10.1186/s13048-021-00896-9
_version_ 1784587044213751808
author Wu, Huijie
Jiang, Shaotao
Zhong, Peiwen
Li, Weiru
Zhang, Siyou
author_facet Wu, Huijie
Jiang, Shaotao
Zhong, Peiwen
Li, Weiru
Zhang, Siyou
author_sort Wu, Huijie
collection PubMed
description BACKGROUND: Mixed cell ovarian adenocarcinoma (MCOA) is a malignant gynecologic tumor consisting of serous, mucous, and papillary tumor cells. However, the clinical features and prognosis of MCOA patients are unclear. METHODS: In this study, univariate and multivariate Cox proportional risk models were performed to identify independent prognostic factors. The Kaplan–Meier method was used to assess the relationship between clinical characteristics and patient survival. Finally, a nomogram was constructed and validated to predict patient survival time, and the C-index was used to evaluate the efficacy of the nomogram. RESULTS: A total of 2,818 patients diagnosed with MCOA were identified, and the 5-year survival rate was 62%. Univariate and multivariate Cox models suggested that age (HR=1.28, 95% CI[1.15,1.44]), grade (HR=1.26, 95% CI[1.12,1.41]), SEER stage (HR=1.63, 95% CI[1.25,2.13]) and AJCC (American Joint Committee on Cancer) stage (HR=1.59, 95% CI[1.36,1.86]) were independent prognostic factors for MCOA patients. After propensity score matching for age, grade, SEER stage, and AJCC stage, the 5-year survival rate was 69.7% for ovarian serous cystadenocarcinoma and 62.9% for ovarian papillary serous cystadenocarcinoma. These results mean that serous adenocarcinoma had the best prognosis of the three pathologic types of ovarian carcinoma (p<0.0001), with no significant difference between papillary serous cystadenocarcinoma and MCOA (p=0.712). Finally, a nomogram consisting of age, grade, SEER stage, and AJCC stage was established and validated to predict the survival time, with C-indices of 0.743 and 0.731, respectively. CONCLUSIONS: In summary, MCOA is uncommon, and age, grade, SEER stage, and AJCC stage are independent prognostic factors. Compared with other common malignant ovarian tumors, MCOA has a poor prognosis.
format Online
Article
Text
id pubmed-8532325
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85323252021-10-25 Development and identification of a prognostic nomogram model for patients with mixed cell adenocarcinoma of the ovary Wu, Huijie Jiang, Shaotao Zhong, Peiwen Li, Weiru Zhang, Siyou J Ovarian Res Research BACKGROUND: Mixed cell ovarian adenocarcinoma (MCOA) is a malignant gynecologic tumor consisting of serous, mucous, and papillary tumor cells. However, the clinical features and prognosis of MCOA patients are unclear. METHODS: In this study, univariate and multivariate Cox proportional risk models were performed to identify independent prognostic factors. The Kaplan–Meier method was used to assess the relationship between clinical characteristics and patient survival. Finally, a nomogram was constructed and validated to predict patient survival time, and the C-index was used to evaluate the efficacy of the nomogram. RESULTS: A total of 2,818 patients diagnosed with MCOA were identified, and the 5-year survival rate was 62%. Univariate and multivariate Cox models suggested that age (HR=1.28, 95% CI[1.15,1.44]), grade (HR=1.26, 95% CI[1.12,1.41]), SEER stage (HR=1.63, 95% CI[1.25,2.13]) and AJCC (American Joint Committee on Cancer) stage (HR=1.59, 95% CI[1.36,1.86]) were independent prognostic factors for MCOA patients. After propensity score matching for age, grade, SEER stage, and AJCC stage, the 5-year survival rate was 69.7% for ovarian serous cystadenocarcinoma and 62.9% for ovarian papillary serous cystadenocarcinoma. These results mean that serous adenocarcinoma had the best prognosis of the three pathologic types of ovarian carcinoma (p<0.0001), with no significant difference between papillary serous cystadenocarcinoma and MCOA (p=0.712). Finally, a nomogram consisting of age, grade, SEER stage, and AJCC stage was established and validated to predict the survival time, with C-indices of 0.743 and 0.731, respectively. CONCLUSIONS: In summary, MCOA is uncommon, and age, grade, SEER stage, and AJCC stage are independent prognostic factors. Compared with other common malignant ovarian tumors, MCOA has a poor prognosis. BioMed Central 2021-10-21 /pmc/articles/PMC8532325/ /pubmed/34674727 http://dx.doi.org/10.1186/s13048-021-00896-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wu, Huijie
Jiang, Shaotao
Zhong, Peiwen
Li, Weiru
Zhang, Siyou
Development and identification of a prognostic nomogram model for patients with mixed cell adenocarcinoma of the ovary
title Development and identification of a prognostic nomogram model for patients with mixed cell adenocarcinoma of the ovary
title_full Development and identification of a prognostic nomogram model for patients with mixed cell adenocarcinoma of the ovary
title_fullStr Development and identification of a prognostic nomogram model for patients with mixed cell adenocarcinoma of the ovary
title_full_unstemmed Development and identification of a prognostic nomogram model for patients with mixed cell adenocarcinoma of the ovary
title_short Development and identification of a prognostic nomogram model for patients with mixed cell adenocarcinoma of the ovary
title_sort development and identification of a prognostic nomogram model for patients with mixed cell adenocarcinoma of the ovary
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8532325/
https://www.ncbi.nlm.nih.gov/pubmed/34674727
http://dx.doi.org/10.1186/s13048-021-00896-9
work_keys_str_mv AT wuhuijie developmentandidentificationofaprognosticnomogrammodelforpatientswithmixedcelladenocarcinomaoftheovary
AT jiangshaotao developmentandidentificationofaprognosticnomogrammodelforpatientswithmixedcelladenocarcinomaoftheovary
AT zhongpeiwen developmentandidentificationofaprognosticnomogrammodelforpatientswithmixedcelladenocarcinomaoftheovary
AT liweiru developmentandidentificationofaprognosticnomogrammodelforpatientswithmixedcelladenocarcinomaoftheovary
AT zhangsiyou developmentandidentificationofaprognosticnomogrammodelforpatientswithmixedcelladenocarcinomaoftheovary